OncoMatch/Clinical Trials/NCT05939661
A Multicenter Single-arm P2 to Evaluate Safety and Efficacy of the Total Neoadjuvant Therapy for cT2 Rectal Cancer
Is NCT05939661 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Chemotherapy for rectal cancer.
Treatment: Chemotherapy — A multicenter single-arm phase 2 study to evaluate safety and efficacy of the total neoadjuvant therapy of short course radiation therapy followed by neoadjuvant oxaliplatin/fluorouracil-based chemotherapy (CAPOX) for cT2 rectal cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Required: Stage CT2N0M0
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: extensive surgery
Exception: excluding CV port placement
extensive surgery (excluding CV port placement) within 4 weeks
Cannot have received: anticancer therapy
Any anticancer therapy within 4 weeks
Cannot have received: radiation therapy
Radiation within 4 weeks
Lab requirements
Blood counts
Neutrophil count: >= 1,500/mm3; Platelet count: >= 10.0 x 10^4 /mm3; Hemoglobin: >=9.0 g/dL
Kidney function
Serum creatinine: 1.5x or less than ULN or creatinine clearance: 45 mL/min or more
Liver function
Total bilirubin: 1.5x or less than ULN; AST, ALT, ALP: 2.5x or less than ULN
criteria for major organ function within 14 days prior to registration: Neutrophil count: >= 1,500/mm3; Platelet count: >= 10.0 x 10^4 /mm3; Hemoglobin: >=9.0 g/dL; Total bilirubin: 1.5x or less than ULN; AST, ALT, ALP: 2.5x or less than ULN; Serum creatinine: 1.5x or less than ULN or creatinine clearance: 45 mL/min or more
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify